Xencor (XNCR) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lessened its stake in Xencor (NASDAQ:XNCR) by 5.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 47,500 shares of the biopharmaceutical company’s stock after selling 2,900 shares during the quarter. Alliancebernstein L.P.’s holdings in Xencor were worth $1,041,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can lifted its holdings in shares of Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Xencor in the third quarter worth $201,000. UBS Asset Management Americas Inc. purchased a new position in shares of Xencor in the fourth quarter worth $205,000. Landscape Capital Management L.L.C. purchased a new position in shares of Xencor in the fourth quarter worth $220,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Xencor in the fourth quarter worth $291,000. 68.82% of the stock is currently owned by hedge funds and other institutional investors.

Shares of XNCR opened at $30.10 on Friday. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $34.63. The firm has a market capitalization of $1,599.21, a P/E ratio of -28.67 and a beta of 1.51.



Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. Xencor had a negative net margin of 137.35% and a negative return on equity of 16.62%. The company had revenue of $10.94 million for the quarter, compared to analysts’ expectations of $15.65 million. analysts forecast that Xencor will post -2.09 EPS for the current fiscal year.

In related news, insider Edgardo Baracchini, Jr. sold 20,000 shares of the business’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $29.64, for a total value of $592,800.00. Following the sale, the insider now owns 20,000 shares in the company, valued at $592,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul A. Foster sold 10,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total transaction of $260,300.00. Following the completion of the sale, the insider now owns 12,419 shares in the company, valued at approximately $323,266.57. The disclosure for this sale can be found here. Insiders sold 105,000 shares of company stock worth $3,101,550 in the last 90 days. 4.03% of the stock is currently owned by company insiders.

Several research firms have recently commented on XNCR. Leerink Swann reissued an “outperform” rating and issued a $36.00 target price on shares of Xencor in a report on Wednesday, March 28th. Cantor Fitzgerald restated a “buy” rating and issued a $37.00 price target on shares of Xencor in a research report on Thursday, March 29th. ValuEngine upgraded shares of Xencor from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, April 7th. Finally, Nomura reduced their price target on shares of Xencor to $28.00 and set a “neutral” rating on the stock in a research report on Thursday, April 5th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $35.17.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/14/xencor-xncr-shares-sold-by-alliancebernstein-l-p.html.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply